Nicolas Musi

EBioMedicine 2019

Open access · CC-BY

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

▲ 1,271

Aging Cell 2018

Open access · CC-BY

Tau protein aggregation is associated with cellular senescence in the brain

▲ 618

EBioMedicine 2023

Open access · CC-BY

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

▲ 286

Nature Medicine 2023

Preprint · OA

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial

▲ 272

The Journal of Prevention of Alzheimer s Disease 2021

Open access · CC-BY

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

▲ 202

PLoS ONE 2011

Open access · CC-BY

Does Reduced IGF-1R Signaling in Igf1r+/− Mice Alter Aging?

▲ 151

Aging Cell 2020

Open access · CC-BY

Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects

▲ 113

EBioMedicine 2022

Open access · CC-BY

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans

▲ 96

Current Molecular Biology Reports 2021

Open access · OA

Cellular Senescence in Idiopathic Pulmonary Fibrosis

▲ 71

Aging Cell 2023

Open access · CC-BY

Age‐dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution

▲ 54

Journal of the American Geriatrics Society 2021

Open access · CC-BY

Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era

▲ 51

GeroScience 2023

Preprint · OA

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

▲ 44

Endocrine Reviews 2023

Open access · OA

Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns

▲ 42

Research Square 2023

Preprint · CC-BY

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

▲ 37

Cell Reports 2023

Open access · CC-BY

Skeletal muscle TFEB signaling promotes central nervous system function and reduces neuroinflammation during aging and neurodegenerative disease

▲ 36

The Journals of Gerontology Series A 2023

Open access · CC0

Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop

▲ 30

Aging Cell 2020

Open access · CC-BY

Acarbose improved survival for Apc+/Min mice

▲ 26

Cell Metabolism 2025

Preprint · OA

Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

▲ 19

Neurotherapeutics 2025

Open access · CC-BY

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

▲ 17

Nature Reviews Endocrinology 2025

Preprint · OA

Translating cellular senescence research into clinical practice for metabolic disease

▲ 10

Alzheimer s & Dementia 2020

Open access · OA

A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes

▲ 10

Research Square 2024

Preprint · CC-BY

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease

▲ 8

Research Square 2025

Preprint · CC-BY

Selecting Appropriate Clinical Trial Endpoints for Geroscience Trials: A Path Towards Consensus

▲ 4

GeroScience 2025

Open access · CC-BY

Short-term mTOR inhibition by rapamycin improves cardiac and endothelial function in older men: a proof-of concept pilot study

▲ 2

The Journal of Clinical Endocrinology & Metabolism 2023

Citation only

NAD-elevating Interventions for Cardiometabolic Disease

▲ 2

CHEST Journal 2018

Open access · OA

TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN

▲ 1

Journal of the Endocrine Society 2024

Open access · CC-BY

6711 Single Nuclei RNA-seq To Map Adipose Cellular Populations And Senescent Cells In Response To A Lifestyle Or Senolytic Intervention In Older Adults With Obesity: A Double-Blind, Placebo-Controlled, Randomized Trial

▲ 0

Diabetes 2024

Citation only

10-PUB: Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Response to a Lifestyle or Senolytic Intervention in Older Adults with Obesity—A Double-Blind, Placebo-Controlled, Randomized Trial

▲ 0

medRxiv 2026

Preprint · CC-BY

A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

▲ 0

Innovation in Aging 2025

Open access · CC-BY

A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

▲ 0

Innovation in Aging 2025

Open access · CC-BY

METFORMIN TO TARGET FRAILTY IN OLDER ADULTS

▲ 0

Diabetes 2025

Citation only

1998-LB: A Two-Year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

▲ 0

Collaborators

Works in the record

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Tau protein aggregation is associated with cellular senescence in the brain

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

Does Reduced IGF-1R Signaling in Igf1r+/− Mice Alter Aging?

Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans

Cellular Senescence in Idiopathic Pulmonary Fibrosis

Age‐dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution

Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

Skeletal muscle TFEB signaling promotes central nervous system function and reduces neuroinflammation during aging and neurodegenerative disease

Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop

Acarbose improved survival for Apc+/Min mice

Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Translating cellular senescence research into clinical practice for metabolic disease

A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease

Selecting Appropriate Clinical Trial Endpoints for Geroscience Trials: A Path Towards Consensus

Short-term mTOR inhibition by rapamycin improves cardiac and endothelial function in older men: a proof-of concept pilot study

NAD-elevating Interventions for Cardiometabolic Disease

TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN

6711 Single Nuclei RNA-seq To Map Adipose Cellular Populations And Senescent Cells In Response To A Lifestyle Or Senolytic Intervention In Older Adults With Obesity: A Double-Blind, Placebo-Controlled, Randomized Trial

10-PUB: Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Response to a Lifestyle or Senolytic Intervention in Older Adults with Obesity—A Double-Blind, Placebo-Controlled, Randomized Trial

A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance

METFORMIN TO TARGET FRAILTY IN OLDER ADULTS

1998-LB: A Two-Year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance